Figure 1From: Recent developments in multiple sclerosis therapeutics Disease-modifying therapies in development target the pathology underlying the stage of multiple sclerosis (MS). Clinical course is indicated by the black line with stepwise increases in disability in early disease caused by relapses and, later, by gradual progression of disability in secondary progressive MS (SPMS) and from disease onset in primary progressive MS (PPMS). Anti-inflammatory therapies are effective in relapsing-remitting MS and SPMS when relapses are still present. Neuroprotective therapies target neurodegeneration in SPMS without relapses and PPMS.Back to article page